Roche's push into the obesity market has received another boost after its experimental drug, enicepatide, helped overweight or obese patients with type 2 diabetes improve blood sugar control while losing an average of 15.5% of their body weight in a mid-stage trial. The results add another potentially important asset to Roche's efforts to challenge obesity-market leaders Eli Lilly and Company (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO). Competition is also growing beyond the two incumbents, with companies including AstraZeneca PLC (NYSE:AZN) and Amgen Inc. (NASDAQ:AMGN) racing to develop new treatments. DON'T MISS: Gilead vs. Abbott: Which Dividend Healthcare Stock Offers the Better Risk-Reward?
Wir zeigen den wichtigsten Punkt oeffentlich. Erstellen Sie ein kostenloses Konto, um den vollstaendigen Artikel zu lesen, ihn zu speichern, zu diskutieren und mit Markt- und OSINT-Kontext zu verbinden.